Virological sustained response to former young intravenous drug abusers with chronic hepatitis C treated by pegylated interferon-α plus ribavirin

Česká verzia

Authors: K. Gazdíková ¹; †f. Gazdík ²; I. Kajaba ¹; D. Hučková ³; D. Daniš ⁴; Ľ. Okruhlica ⁵
Authors place of work: Fakulta ošetrovateľstva a zdravotníckych odborných štúdií Slovenskej zdravotníckej univerzity Bratislava, Slovenská republika, rektorka Dr. h. c. prof. PhDr. Dana Farkašová, CSc. ¹; Oddelenie imunológie a imunotoxikológie Slovenskej zdravotníckej univerzity Bratislava, Slovenská republika, rektorka Dr. h. c. prof. PhDr. Dana Farkašová, CSc. ²; HPL spol. s r. o., Bratislava, Slovenská republika, riaditeľ MUDr. Juraj Hanzen ³; Ústav patológie Slovenskej zdravotníckej univerzity Bratislava, Slovenská republika, rektorka Dr. h. c. prof. PhDr. Dana Farkašová, CSc. ⁴; Inštitút drogových závislostí, Centrum pre liečbu drogových závislostí Bratislava, Slovenská republika, riaditeľ MUDr. Ľubomír Okruhlica, PhD. ⁵
Published in the journal: Vnitř Lék 2012; 58(2): 104-109
Category: Original Contributions

Summary

Introduction:
The most risk group with high rate of infection of viral hepatitis C represents the former drug abusers (IDUs).

Objectives:
The objectives of the clinical study were to assess the sustained virological response (SVR) in the group of former IDUs with chronic hepatitis C (CHC) treated with pegylated interferon-α and ribavirin.

Patients and methods:
Of 293 previously untreated (naive) former IDUs with CHC who have started treatment, we assessed 239 (69 women, 170 men) with an average age of 27 years who completed treatment and received a follow-up examination after 24 weeks. Prior to therapy abstinence to drug abuse 6 and more months has been required. The CHC has been diagnostics by the standard virological diagnostic tests, increased activity of aminotranferases (ALT) and histology of liver biopsy. Patients were treated with combined immunomodulatory therapy in the standard duration and standard regimen. SVR was considered if qualitative test HCV RNA was negative 24 weeks after the completion of the treatment.

Results:
End-of-treatment virological response was in 224/94 % patients. Overall SVR rate was 95 %, 227 subjects had negative HCV RNA and only 12 patients no response. During treatment there was a statistically significant decrease in ALT. Treatment was accompanied by the expected side effects.

Conclusion:
Young age, short duration of HCV infection, high prevalence of genotype 3 and low grade of liver fibrosis in majority of patients and good adherence of patients to treatment were crucial predictive factors resulting in high SVR.

Key words:
chronic hepatitis C – pegylated interferon-α – ribavirin – former intravenous drug abusers

Zdroje

1. Gazdik F, Bednarova A, Kazar J et al. Hepatitis C virus genotypes distribution among risk groups in the Slovak Republic. Hepatology 2001; 34: 559.

2. Gazdík F, Gazdíková K, Kajaba I et al. Séroprevalencia HCV infekcie a distribúcia genotypov u intravenóznych drogovo závislých jedincov v regióne západného Slovenska. Slov Lekár 2006; 16: 275–278.

3. Gazdik F, Pijak M, Kazar J et al. Hepatitis C virus prevalence among general population and risk groups in the Slovak Republic. Hepatology 2001; 34: 559.

4. Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology 2000; 31: 1014–1018.

5. Seef LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35–S46.

6. Biggins SW, Terrault NA. Treatment of recurrent hepatitis C after liver transplantation. Clin Liver Dis 2005; 9: 505–523.

7. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696–699.

8. Oltman M, Kužela L. Vírus hepatitídy C a imunitný systém. Trendy HEPA 2010; 1: 18–22.

9. Matheï C, Wollants E, Verbeck J et al. Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: Association of genotype with clinical parameters and with sex- and drug-related risk behaviours. Eur J Clin Microbial Infect Dis 2005; 24: 514–522.

10. Thomson BJ, Finch RG. Hepatitis C virus infection. Clin Microbiol Infect 2005; 11: 86–94.

11. Koncova-Fejdiova K, Gazdik F, Hruzikova H. Comparison of the HCV genotypes between active drug users and patients in therapeutic process in the Slovak Republic in the years 2004––2005. J Clin Virology 2006; 26: 108.

12. Krekulová L, Rehák V, Strunecký O et al. Current situation and trends in the hepatitis C genotype distribution among injecting drug users in the Czech Republic. Epidemiol Mikrobiol Imunol 2009; 58: 84–89.

13. Fried MW, Siffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982.

14. Hadziyannis SJ, Cheinquer H, Morgan T et al. Peginterferon alfa-2A (40KD) (Pegasys) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double--blind, multicentre study examining effect of duration of treatment and RBV dose. J Hepatol 2002; 36: 3.

15. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.

16. Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993–999.

17. Urbánek P, Subhanová I, Janoušková E et al. Účinnost terapie pegylovaným interferonem a ribavirinem u pacientů s chronickou HCV infekcí. Vnitř Lék 2009; 55: 474–479.

18. He LL, Chen Z, Chen Y et al. Association between influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients. Zhonghua Gan Zang Bing Za Zhi 2011: 19: 34–37.

19. Schuppan D, Krebs A, Bauer M et al. Hepatitis C and liver fibrosis. Cell Death Differ 2003; 10: S59–S67.

20. Husa P, Šlesinger P, Štroblová H et al. Ovlivnění úspešnosti léčby chronické hepatitdy C hmotností a pohlavím pacienta a výši vstupní viremie. Vnitř Lék 2006; 52: 590–595.

21. McHutchison JG, Manns M, Patel K et al. International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061–1069.

22. Ochi H, Maekawa T, Abe H et al. IL-28B predicts response to chronic hepatitis C therapy – fine-mapping and replication study in Asian populations. J Gen Virol 2011; 92: 1071–1081.

23. Furusyo N, Murata M, Ogawa E et al. Ribavirin concentration in the later stages of 48 week pegylated interferon-α-2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response. J Antimicrob Chemother 2011; 66: 1127–1139.